Assaf Weiner (@AssafWeiner) profile picture

Assaf Weiner

@AssafWeiner
Joined July 2016
  • Tweets13
  • Following67
  • Followers54
Assaf Weiner retweeted
Immunai (@Immunaitech) profile picture
Immunai@Immunaitech16 Oct 2025
Proud to expand our work with @AstraZeneca into inflammatory bowel disease. IBD affects 10M+ people worldwide, with many still cycling through treatments. With Immunai’s IDE™ and AMICA™, we’re uncovering and exploring new immune targets. @FierceBiotech: tinyurl.com/48htfzzy
AstraZeneca pens fresh IBD collab with long-term AI partner Immunai worth $85M

AstraZeneca pens fresh IBD collab with long-term AI partner Immunai worth $85M

AstraZeneca has returned to its longtime artificial intelligence partner Immunai with a new deal worth up to $85 million to advance a suitable target for a new inflammatory bowel disease (IBD) ther |...

fiercebiotech.com
3
1
6
655
Assaf Weiner retweeted
Immunai (@Immunaitech) profile picture
Immunai@Immunaitech19 Nov 2024
Honored to be named Immunology Innovation of the Year by the @BioTech_Awards! Our commitment to advancing immunology with AI can help pharma teams understand immune responses like never before. biotechbreakthroughawards.co…
2024 Winners - BioTech Breakthrough Awards

2024 Winners - BioTech Breakthrough Awards

2024 Winners BioPharma Immunomodulatory Solution of the Year Monoclonal Antibody Innovation of the Year Monoclonal Antibody Solution of the Year Overall BioPharma Company of the Year Overall BioPha...

biotechbreakthroughawards.com
2
2
219
Researchers from @IdoAmitLab in collaboration with physicians from Tel Aviv Sourasky Medical Center, have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma bit.ly/2ZG8nWU
Image from Weizmann Institute (@WeizmannScience)
7
21
Happy to help Ido Amit on this super cool method: Co-ChIP -histone mark co-occurrence at single-molecule resolution dx.doi.org/10.1038/nbt.3652
1
2
6
Load more